Summary
Humana Medicare Advantage now requires prior authorization for SGLT2 inhibitor medications (Steglatro, Segluromet, Invokana, Invokamet, Invokamet XR) for Type 2 diabetes patients. Patients must have tried or have contraindications to both empagliflozin AND dapagliflozin before these medications will be approved.
Get alerts when payers change rules like this one
We check Humana and other payers every day and email you when a change matches your specialty and state.
Get Humana alertsPolicy Monitoring is free. No card required.
What to do
Action · 4 steps
01Before January 1, 2026: Providers must obtain prior authorization for SGLT2 inhibitors (Steglatro, Segluromet, Invokana, Invokamet, Invokamet XR) for Humana Medicare Advantage patients.
02Document that patients have Type 2 diabetes and have tried or have contraindications to both empagliflozin AND dapagliflozin.
03Visit www.humana.com/PAL for preauthorization requirements.
04Claims will be denied without proper prior authorization.
Original notice
SGLT2 Inhibitors (New)
mcp.humana.com · Always check the source before changing claims.